课题基金 / 基金详情

Upgrade to 600 MHz NMR spectrometer

Upgrade to 600 MHz NMR spectrometer
升级至 600 MHz NMR 波谱仪
批准号:
BB/R000727/1
负责人:
Michael Williamson
金额:
$57.38万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --

项目摘要

项目成果

Michael Williamson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Nuclear Magnetic Resonance (NMR) is a spectroscopic technique closely related to Magnetic Resonance Imaging (MRI). It is a very versatile technique. Its biggest application lies in its ability to provide detailed information on interactions between molecules. Proteins up to about 30 kDa (250 amino acid residues) can have backbone signals assigned rapidly and almost automatically. This means that we can rapidly and simply work out which signal comes from which amino acid, thereby providing a fingerprint of the protein. Addition of a ligand (for example a small molecule drug, or another protein) produces changes in signals, which are straightforwardly analysed to determine where the ligand is binding, and often to produce a binding affinity. With larger proteins, similar information can be obtained in slightly different ways although with rather more experimental effort. Very large proteins (including membrane proteins and receptors in intact cells) are still amenable to investigation, and there are straightforward techniques for identifying which ligands bind to such targets, and which parts of the ligands are most closely in contact. NMR has many other uses. It can be used to calculate the structures of proteins in solution, to analyse local and global mobility, to look at structural change on alteration of solution conditions or addition of ligands, to measure local pKa values of charged sidechains, to analyse the metabolites present in complex mixtures such as body fluids, to follow metabolic and enzymatic processes, and much more. Extracting such information is not always straightforward and often requires expert advice and intervention.Currently we carry out many such analyses on a range of targets, often as a result of problems being investigated by external users that we are asked to advise on. Selection of projects is made on the basis of scientific importance rather than funding, although funding is clearly of considerable importance. Our current equipment is old and becoming obsolete, and is therefore likely to fail catastrophically at some point over the next few years. We are looking to replace it with new equipment, which has very similar capabilities, although the intervening years have led to improvements in many systems, for example more stable electronics and more rapid switching. The upgraded instrument will therefore be able to do the same things as our current instrument, but better and faster, with fewer instrumental artifacts and limitations. It will have some new capabilities, which will enable us to carry out a wider range of investigations, and will bring it up to the highest international standards. The current instrument has lasted 18 years: we expect the upgraded instrument to last at least another 10 and hopefully considerably longer. The funding required is thus a very cost-effective solution to the provision of world-class NMR facilities. The upgraded instrument will be used for a wide range of projects, with users mainly from Sheffield but also further afield. These include investigation of amyloid proteins (the cause of Alzheimer's disease); fundamental research on protein stability and solubility in solution; work on the mechanism of kinases and phosphoryl transferases (key regulatory enzymes within metabolic pathways; investigations on bacterial proteins that recognise specific parts of bacterial cell walls and could therefore be used as a basis for both antibiotics and novel diagnostic tools; investigations of the function of specific proteins; and the development of high-pressure NMR as a tool for investigating the relatively low-population active forms of proteins. The instrument therefore provides an important resource for many problems in biomolecular research.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.str.2023.05.012
发表时间: 2023-08-03
期刊: STRUCTURE
影响因子: 5.7
作者: [Fowler,Nicholas J., Albalwi,Marym F., Williamson,Mike P.]
通讯作者: Williamson,Mike P.
DOI: 10.1016/j.sjbs.2022.103526
发表时间: 2023-02
期刊: SAUDI JOURNAL OF BIOLOGICAL SCIENCES
影响因子: 4.4
作者: [Hassan, Mahreen U., Williamson, Mike P.]
通讯作者: Williamson, Mike P.
DOI: 10.1038/s41589-019-0393-4
发表时间: 2020-01-01
期刊: NATURE CHEMICAL BIOLOGY
影响因子: 14.8
作者: [Gonzalez-Delgado, Luz S., Walters-Morgan, Hannah, Mesnage, Stephane]
通讯作者: Mesnage, Stephane
DOI: 10.1038/s41467-020-20177-1
发表时间: 2020-12-18
期刊: Nature communications
影响因子: 16.6
作者: [Fowler NJ, Sljoka A, Williamson MP]
通讯作者: Williamson MP
Validation of NMR protein structures using FIRST and RCI
  • 批准号:
    BB/P020038/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $36.64万
  • 财政年份:
    2018
  • 负责人:
    Michael Williamson
  • 依托单位:
A World-Leading National Network for NMR in the Physical and Life Science: Very-High Field Infrastructure at Sheffield
  • 批准号:
    EP/S01358X/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $107.61万
  • 财政年份:
    2018
  • 负责人:
    Michael Williamson
  • 依托单位:
To Hofmeister and beyond: an improved understanding of protein solubility and stability
  • 批准号:
    BB/P007066/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $41.07万
  • 财政年份:
    2017
  • 负责人:
    Michael Williamson
  • 依托单位:
Internal dynamics in the enzyme barnase
  • 批准号:
    BB/J014966/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $51.57万
  • 财政年份:
    2012
  • 负责人:
    Michael Williamson
  • 依托单位:
国内基金
海外基金
BRAF V600E突变型结直肠癌的免疫逃逸机制研究
  • 批准号:
    2025JJ40080
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    韩莹
  • 依托单位:
靶向BRAF V600E激酶分子胶降解剂的设 计合成及其作用机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    黎盛荣
  • 依托单位:
基于AI的甲状腺乳头状癌BRAFV600E基因突变和复发风险模型研究
  • 批准号:
    JCZRLH202500640
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
靶向PLK1通过铁死亡途径逆转BRAFV600E结直肠癌对BRAF和EGFR抑制剂耐药的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2024
  • 负责人:
    潘京华
  • 依托单位: